Published in AIDS on November 01, 2009
Hormonal contraception and HIV-1 infection: medroxyprogesterone acetate suppresses innate and adaptive immune mechanisms. Endocrinology (2013) 1.81
Family planning and HIV: strange bedfellows no longer. AIDS (2009) 1.28
Hormonal contraception and HIV-1 transmission. Am J Reprod Immunol (2010) 1.13
Reproductive healthcare needs and desires in a cohort of HIV-positive women. Infect Dis Obstet Gynecol (2012) 1.10
Hormonal contraceptive use and HIV disease progression among women in Uganda and Zimbabwe. J Acquir Immune Defic Syndr (2011) 1.06
Preconception and contraceptive care for women living with HIV. Infect Dis Obstet Gynecol (2012) 0.99
Hormonal contraceptive use and risk of HIV-1 disease progression. AIDS (2013) 0.92
What works to meet the sexual and reproductive health needs of women living with HIV/AIDS. J Int AIDS Soc (2011) 0.91
Previous reproductive history and post-natal family planning among HIV-infected women in Ukraine. Hum Reprod (2010) 0.81
Awareness and interest in intrauterine contraceptive device use among HIV-positive women in Cape Town, South Africa. Infect Dis Obstet Gynecol (2012) 0.79
Associations of hormonal contraceptive use with measures of HIV disease progression and antiretroviral therapy effectiveness. Contraception (2015) 0.78
Contraception in HIV-positive female adolescents. AIDS Res Ther (2011) 0.78
Beyond the Pap Smear: Gender-responsive HIV Care for Women. Yale J Biol Med (2016) 0.77
Hormonal contraceptive use and discontinuation among HIV-infected women in Uganda and Zimbabwe. J Acquir Immune Defic Syndr (2013) 0.77
Lower concentrations of chemotactic cytokines and soluble innate factors in the lower female genital tract associated with the use of injectable hormonal contraceptive. J Reprod Immunol (2015) 0.77
Getting to zero the biomedical way in Africa: outcomes of deliberation at the 2013 Biomedical HIV Prevention Forum in Abuja, Nigeria. BMC Proc (2014) 0.75
Hormonal Contraception and Risk of Psychiatric and Other Noncommunicable Diseases in HIV-Infected Women. J Womens Health (Larchmt) (2015) 0.75
Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science (1996) 18.38
CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med (2004) 13.55
Th17: an effector CD4 T cell lineage with regulatory T cell ties. Immunity (2006) 10.53
Primary HIV-1 infection is associated with preferential depletion of CD4+ T lymphocytes from effector sites in the gastrointestinal tract. J Exp Med (2004) 9.11
Expression of CD57 defines replicative senescence and antigen-induced apoptotic death of CD8+ T cells. Blood (2002) 6.73
Progesterone implants enhance SIV vaginal transmission and early virus load. Nat Med (1996) 5.63
Hormonal contraception and the risk of HIV acquisition. AIDS (2007) 5.05
Expanding the effector CD4 T-cell repertoire: the Th17 lineage. Curr Opin Immunol (2006) 3.78
A gender gap in autoimmunity. Science (1999) 3.33
Immune activation and CD8+ T-cell differentiation towards senescence in HIV-1 infection. PLoS Biol (2004) 3.20
HIV-1-driven regulatory T-cell accumulation in lymphoid tissues is associated with disease progression in HIV/AIDS. Blood (2006) 2.95
Hormonal contraception, vitamin A deficiency, and other risk factors for shedding of HIV-1 infected cells from the cervix and vagina. Lancet (1997) 2.88
Higher set point plasma viral load and more-severe acute HIV type 1 (HIV-1) illness predict mortality among high-risk HIV-1-infected African women. Clin Infect Dis (2006) 2.65
HIV inhibits CD4+ T-cell proliferation by inducing indoleamine 2,3-dioxygenase in plasmacytoid dendritic cells. Blood (2006) 2.58
The value of contraception to prevent perinatal HIV transmission. Sex Transm Dis (2006) 2.49
Molecular and clinical epidemiology of CXCR4-using HIV-1 in a large population of antiretroviral-naive individuals. J Infect Dis (2005) 2.42
Detection of HIV DNA in cervical and vaginal secretions. Prevalence and correlates among women in Nairobi, Kenya. JAMA (1993) 2.41
Accelerated immune senescence and HIV-1 infection. Exp Gerontol (2007) 2.41
CD4+ T cell surface CCR5 density as a determining factor of virus load in persons infected with human immunodeficiency virus type 1. J Infect Dis (2000) 2.34
A randomized trial of the intrauterine contraceptive device vs hormonal contraception in women who are infected with the human immunodeficiency virus. Am J Obstet Gynecol (2007) 2.17
Predictors of disease progression in HIV infection: a review. AIDS Res Ther (2007) 2.05
Infection with multiple human immunodeficiency virus type 1 variants is associated with faster disease progression. J Virol (2003) 1.96
Cutting edge: progesterone regulates IFN-alpha production by plasmacytoid dendritic cells. J Immunol (2008) 1.44
Maternal mortality and maternity care from 1990 to 2005: uneven but important gains. Reprod Health Matters (2007) 1.39
Effect of estradiol on cytokine secretion by proteolipid protein-specific T cell clones isolated from multiple sclerosis patients and normal control subjects. J Immunol (1997) 1.39
Steroid hormone regulation of cytokine secretion by proteolipid protein-specific CD4+ T cell clones isolated from multiple sclerosis patients and normal control subjects. J Immunol (1998) 1.38
Proinflammatory cytokines in HIV disease-a review and rationale for new therapeutic approaches. AIDS Rev (2005) 1.35
Progestin-based contraceptive suppresses cellular immune responses in SHIV-infected rhesus macaques. Virology (2006) 1.34
The effect of pregnancy on survival in women infected with HIV: a systematic review of the literature and meta-analysis. Br J Obstet Gynaecol (1998) 1.32
The effect of hormonal contraception on genital tract shedding of HIV-1. AIDS (2004) 1.32
Estradiol enhances primary antigen-specific CD4 T cell responses and Th1 development in vivo. Essential role of estrogen receptor alpha expression in hematopoietic cells. Eur J Immunol (2003) 1.29
Hormonal contraception and HIV-1 disease progression among postpartum Kenyan women. AIDS (2007) 1.28
Effect of hormonal contraceptive use on plasma HIV-1-RNA levels among HIV-infected women. AIDS (2003) 1.20
Hormonal contraception and risk of HIV-1 acquisition: results of a 10-year prospective study. AIDS (2004) 1.19
Oral contraceptive use induces upregulation of the CCR5 chemokine receptor on CD4(+) T cells in the cervical epithelium of healthy women. J Reprod Immunol (2002) 1.15
Risk of HIV infection in oral contraceptive pill users: a meta-analysis. J Acquir Immune Defic Syndr (1999) 1.11
Abrogation of attenuated lentivirus-induced protection in rhesus macaques by administration of depo-provera before intravaginal challenge with simian immunodeficiency virus mac239. J Infect Dis (2004) 1.11
Effect of contraceptive methods on natural history of HIV: studies from the Mombasa cohort. J Acquir Immune Defic Syndr (2005) 1.06
Molecular virology and immunology of HIV infection. J Allergy Clin Immunol (2002) 1.05
Relationship of hormonal contraception and cervical ectopy as measured by computerized planimetry to chlamydial infection in adolescents. Sex Transm Dis (2000) 1.02
Regulatory effects of estriol on T cell migration and cytokine profile: inhibition of transcription factor NF-kappa B. J Neuroimmunol (2002) 0.97
Ex vivo effect of estrogen and progesterone compared with dexamethasone on cell-mediated immunity of HIV-infected and uninfected subjects. J Acquir Immune Defic Syndr (2007) 0.96
Estrogen and progesterone receptors in some human myeloma cell lines and murine hybridomas. J Steroid Biochem (1988) 0.93
Estrogen stimulates transcription of human immunodeficiency virus type 1 (HIV-1). Int Immunopharmacol (2005) 0.87
Progesterone receptor in chicken bursa of Fabricius and thymus: evidence for expression in B-lymphocytes. Mol Cell Endocrinol (1998) 0.86
Progesterone directly and indirectly affects perforin expression in cytolytic cells. Am J Reprod Immunol (1999) 0.86
Impact of pregnancy and menopause on CD4 cell counts. J Acquir Immune Defic Syndr (2005) 0.82
Progesterone induced blocking factor (PIBF) mediates progesterone induced suppression of decidual lymphocyte cytotoxicity. Am J Reprod Immunol (2002) 0.82
Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med (2007) 12.93
Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med (2010) 10.90
Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet (2008) 8.73
Clinical outcomes and CD4 cell response in children receiving antiretroviral therapy at primary health care facilities in Zambia. JAMA (2007) 7.00
Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study. AIDS (2003) 5.61
Incidence and risk factors for new-onset diabetes in HIV-infected patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study. Diabetes Care (2008) 4.10
Antiretroviral treatment for children with peripartum nevirapine exposure. N Engl J Med (2010) 3.81
Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: role of CD4+ Cell counts and HIV RNA levels during follow-up. J Infect Dis (2008) 3.35
Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J Infect Dis (2010) 3.30
Impact of antiretroviral therapy on incidence of pregnancy among HIV-infected women in Sub-Saharan Africa: a cohort study. PLoS Med (2010) 3.27
Antiretroviral treatment and prevention of peripartum and postnatal HIV transmission in West Africa: evaluation of a two-tiered approach. PLoS Med (2007) 2.93
Advanced HIV disease at entry into HIV care and initiation of antiretroviral therapy during 2006-2011: findings from four sub-saharan African countries. Clin Infect Dis (2013) 2.91
Persistent minority K103N mutations among women exposed to single-dose nevirapine and virologic response to nonnucleoside reverse-transcriptase inhibitor-based therapy. Clin Infect Dis (2009) 2.75
Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study. Eur J Cardiovasc Prev Rehabil (2010) 2.70
Microfluidics-based diagnostics of infectious diseases in the developing world. Nat Med (2011) 2.68
Reuse of nevirapine in exposed HIV-infected children after protease inhibitor-based viral suppression: a randomized controlled trial. JAMA (2010) 2.67
Rates and types of psychiatric disorders in perinatally human immunodeficiency virus-infected youth and seroreverters. J Child Psychol Psychiatry (2009) 2.57
Nevirapine versus ritonavir-boosted lopinavir for HIV-infected children. N Engl J Med (2012) 2.50
The role of psychosocial and family factors in adherence to antiretroviral treatment in human immunodeficiency virus-infected children. Pediatr Infect Dis J (2004) 2.46
Antiretroviral treatment in resource-poor settings: clinical research priorities. Lancet (2002) 2.36
Routine offering of HIV testing to hospitalized pediatric patients at university teaching hospital, Lusaka, Zambia: acceptability and feasibility. J Acquir Immune Defic Syndr (2009) 2.30
Antiretroviral therapy in pregnant women with advanced HIV disease and pregnancy outcomes in Abidjan, Côte d'Ivoire. AIDS (2008) 2.14
Antiretroviral therapy in antenatal care to increase treatment initiation in HIV-infected pregnant women: a stepped-wedge evaluation. AIDS (2010) 2.11
Introducing a multi-site program for early diagnosis of HIV infection among HIV-exposed infants in Tanzania. BMC Pediatr (2010) 2.09
Initial response to protease-inhibitor-based antiretroviral therapy among children less than 2 years of age in South Africa: effect of cotreatment for tuberculosis. J Infect Dis (2010) 2.09
Risks and benefits of lifelong antiretroviral treatment for pregnant and breastfeeding women: a review of the evidence for the Option B+ approach. Curr Opin HIV AIDS (2013) 2.07
Initiation of highly active antiretroviral therapy among pregnant women in Cape Town, South Africa. Trop Med Int Health (2010) 2.06
Switching children previously exposed to nevirapine to nevirapine-based treatment after initial suppression with a protease-inhibitor-based regimen: long-term follow-up of a randomised, open-label trial. Lancet Infect Dis (2012) 2.05
Individual and household level factors associated with malaria incidence in a highland region of Ethiopia: a multilevel analysis. Am J Trop Med Hyg (2009) 1.96
Mother-to-child transmission of HIV-1: timing and implications for prevention. Lancet Infect Dis (2006) 1.93
Scale-up of HIV care and treatment: can it transform healthcare services in resource-limited settings? AIDS (2007) 1.91
Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003-2006. Clin Infect Dis (2008) 1.90
Sexual and drug use behavior in perinatally HIV-infected youth: mental health and family influences. J Am Acad Child Adolesc Psychiatry (2009) 1.88
Acquired rifamycin resistance with twice-weekly treatment of HIV-related tuberculosis. Am J Respir Crit Care Med (2005) 1.85
Mortality trends in the US Perinatal AIDS Collaborative Transmission Study (1986-2004). Clin Infect Dis (2011) 1.83
Sensitivity analysis and potential uses of a novel gamma interferon release assay for diagnosis of tuberculosis. J Clin Microbiol (2006) 1.83
Early clinical and programmatic outcomes with tenofovir-based antiretroviral therapy in Zambia. J Acquir Immune Defic Syndr (2010) 1.82
Global development. Family planning and the Millennium Development Goals. Science (2010) 1.78
Focus on women: linking HIV care and treatment with reproductive health services in the MTCT-Plus Initiative. Reprod Health Matters (2005) 1.77
Metabolic abnormalities and body composition of HIV-infected children on Lopinavir or Nevirapine-based antiretroviral therapy. Arch Dis Child (2012) 1.73
PEPFAR, health system strengthening, and promoting sustainability and country ownership. J Acquir Immune Defic Syndr (2012) 1.72
Mobile device for disease diagnosis and data tracking in resource-limited settings. Clin Chem (2013) 1.72
Strengthening health systems at facility-level: feasibility of integrating antiretroviral therapy into primary health care services in lusaka, zambia. PLoS One (2010) 1.71
Family-centred approaches to the prevention of mother to child transmission of HIV. J Int AIDS Soc (2010) 1.67
Cohort profile: the paediatric antiretroviral treatment programmes in lower-income countries (KIDS-ART-LINC) collaboration. Int J Epidemiol (2007) 1.60
Incidence and prevalence of HIV encephalopathy in children with HIV infection receiving highly active anti-retroviral therapy (HAART). J Pediatr (2005) 1.59
Gender and care: access to HIV testing, care, and treatment. J Acquir Immune Defic Syndr (2009) 1.55
Optimization of antiretroviral therapy in HIV-infected children under 3 years of age: a systematic review. AIDS (2014) 1.52
Immune reconstitution inflammatory syndrome among HIV-infected South African infants initiating antiretroviral therapy. AIDS (2009) 1.51
Retention of HIV-infected children on antiretroviral treatment in HIV care and treatment programs in Kenya, Mozambique, Rwanda, and Tanzania. J Acquir Immune Defic Syndr (2013) 1.47
Implementation and operational research: the impact of option B+ on the antenatal PMTCT cascade in Lilongwe, Malawi. J Acquir Immune Defic Syndr (2015) 1.47
A pilot study of once-daily antiretroviral therapy integrated with tuberculosis directly observed therapy in a resource-limited setting. J Acquir Immune Defic Syndr (2004) 1.42
HIV-1 drug resistance at antiretroviral treatment initiation in children previously exposed to single-dose nevirapine. AIDS (2011) 1.41
The impact of perinatal HIV infection on older school-aged children's and adolescents' receptive language and word recognition skills. AIDS Patient Care STDS (2009) 1.38
Care and treatment of HIV-infected children in Africa: issues and challenges at the district hospital level. Pediatr Infect Dis J (2007) 1.38
Psychiatric disorders in youth with perinatally acquired human immunodeficiency virus infection. Pediatr Infect Dis J (2006) 1.37
Utilization of cervical cancer screening services and trends in screening positivity rates in a 'screen-and-treat' program integrated with HIV/AIDS care in Zambia. PLoS One (2013) 1.37
CD4+ cell count testing more effective than HIV disease clinical staging in identifying pregnant and postpartum women eligible for antiretroviral therapy in resource-limited settings. J Acquir Immune Defic Syndr (2010) 1.35
Ritonavir-based highly active antiretroviral therapy in human immunodeficiency virus type 1-infected infants younger than 24 months of age. Pediatr Infect Dis J (2005) 1.34
Comparing two service delivery models for the prevention of mother-to-child transmission (PMTCT) of HIV during transition from single-dose nevirapine to multi-drug antiretroviral regimens. BMC Public Health (2010) 1.34
Patients enrolled in HIV care in Mozambique: baseline characteristics and follow-up outcomes. J Acquir Immune Defic Syndr (2011) 1.32
Treatment of young children with HIV infection: using evidence to inform policymakers. PLoS Med (2012) 1.32
Immunogenicity, safety, and predictors of response after a pneumococcal conjugate and pneumococcal polysaccharide vaccine series in human immunodeficiency virus-infected children receiving highly active antiretroviral therapy. Pediatr Infect Dis J (2006) 1.32
Comparison of 2 doses of liposomal amphotericin B and conventional amphotericin B deoxycholate for treatment of AIDS-associated acute cryptococcal meningitis: a randomized, double-blind clinical trial of efficacy and safety. Clin Infect Dis (2010) 1.32
Adherence and virologic suppression during the first 24 weeks on antiretroviral therapy among women in Johannesburg, South Africa - a prospective cohort study. BMC Public Health (2011) 1.30
Dyslipidemia among perinatally HIV-infected children enrolled in the PACTS-HOPE cohort, 1999-2004: a longitudinal analysis. J Acquir Immune Defic Syndr (2006) 1.27
Population genetic estimation of the loss of genetic diversity during horizontal transmission of HIV-1. BMC Evol Biol (2006) 1.27
Interruption of antiretroviral therapy is associated with increased plasma cystatin C. AIDS (2009) 1.26
Rapid development of antiretroviral drug resistance mutations in HIV-infected children less than two years of age initiating protease inhibitor-based therapy in South Africa. AIDS Res Hum Retroviruses (2011) 1.22
Effect of bimonthly supplementation with oral cholecalciferol on serum 25-hydroxyvitamin D concentrations in HIV-infected children and adolescents. Pediatrics (2009) 1.22
Prevalence and change in psychiatric disorders among perinatally HIV-infected and HIV-exposed youth. AIDS Care (2012) 1.21
Decentralization of pediatric HIV care and treatment in five sub-Saharan African countries. J Acquir Immune Defic Syndr (2013) 1.20
Acceptability of tenofovir gel as a vaginal microbicide by US male participants in a Phase I clinical trial (HPTN 050). AIDS Care (2007) 1.20
Initiation of antiretroviral therapy among pregnant women in resource-limited countries: CD4+ cell count response and program retention. AIDS (2010) 1.19
Boarder babies with AIDS in harlem: lessons in applied public health. Am J Public Health (2002) 1.17
CD4+ response and subsequent risk of death among patients on antiretroviral therapy in Lusaka, Zambia. J Acquir Immune Defic Syndr (2009) 1.15
Strengthening Health Systems for Chronic Care: Leveraging HIV Programs to Support Diabetes Services in Ethiopia and Swaziland. J Trop Med (2012) 1.13
Poor early virologic performance and durability of abacavir-based first-line regimens for HIV-infected children. Pediatr Infect Dis J (2013) 1.12
PEPFAR programs linked to more deliveries in health facilities by African women who are not infected with HIV. Health Aff (Millwood) (2012) 1.10
Induction therapy with protease-inhibitors modifies the effect of nevirapine resistance on virologic response to nevirapine-based HAART in children. Clin Infect Dis (2011) 1.10
Option B+ for prevention of mother-to-child transmission of HIV in resource-constrained settings: great promise but some early caution. AIDS (2014) 1.10
Adapting a Family-Based HIV Prevention Program for HIV-Infected Preadolescents and Their Families: Youth, Families and Health Care Providers Coming Together to Address Complex Needs. Soc Work Ment Health (2007) 1.09
A temporal-spatial analysis of malaria transmission in Adama, Ethiopia. Am J Trop Med Hyg (2009) 1.08
Family experiences with pediatric antiretroviral therapy: responsibilities, barriers, and strategies for remembering medications. AIDS Patient Care STDS (2008) 1.07
Impact of antiretroviral drugs in pregnant women and their children in Africa: HIV resistance and treatment outcomes. J Infect Dis (2013) 1.07
High prevalence of the metabolic syndrome in HIV-infected patients: impact of different definitions of the metabolic syndrome. AIDS (2010) 1.07
The reliability of reports of medical adherence from children with HIV and their adult caregivers. J Pediatr Psychol (2003) 1.07
Drug resistance among newly diagnosed HIV-infected children in the era of more efficacious antiretroviral prophylaxis. AIDS (2014) 1.07
Genital herpes simplex virus infection and perinatal transmission of human immunodeficiency virus. Obstet Gynecol (2005) 1.06
Ultrasensitive p24 antigen assay for diagnosis of perinatal human immunodeficiency virus type 1 infection. J Clin Microbiol (2007) 1.06